Literature DB >> 27003442

GHR/PRLR Heteromultimer Is Composed of GHR Homodimers and PRLR Homodimers.

Ying Liu1, Yue Zhang1, Jing Jiang1, Peter E Lobie1, Ramasamy Paulmurugan1, John F Langenheim1, Wen Y Chen1, Kurt R Zinn1, Stuart J Frank1.   

Abstract

GH receptor (GHR) and prolactin (PRL) receptor (PRLR) are homologous transmembrane cytokine receptors. Each prehomodimerizes and ligand binding activates Janus Kinase 2 (JAK2)-signal transducer and activator of transcription (STAT) signaling pathways by inducing conformational changes within receptor homodimers. In humans, GHR is activated by GH, whereas PRLR is activated by both GH and PRL. We previously devised a split luciferase complementation assay, in which 1 receptor is fused to an N-terminal luciferase (Nluc) fragment, and the other receptor is fused to a C-terminal luciferase (Cluc) fragment. When receptors approximate, luciferase activity (complementation) results. Using this assay, we reported ligand-independent GHR-GHR complementation and GH-induced complementation changes characterized by acute augmentation above basal signal, consistent with induction of conformational changes that bring GHR cytoplasmic tails closer. We also demonstrated association between GHR and PRLR in T47D human breast cancer cells by coimmunoprecipitation, suggesting that, in addition to forming homodimers, these receptors form hetero-assemblages with functional consequences. We now extend these analyses to examine basal and ligand-induced complementation of coexpressed PRLR-Nluc and PRLR-Cluc chimeras and coexpressed GHR-Nluc and PRLR-Cluc chimeras. We find that PRLR-PRLR and GHR-PRLR form specifically interacting ligand-independent assemblages and that either GH or PRL augments PRLR-PRLR complementation, much like the GH-induced changes in GHR-GHR dimers. However, in contrast to the complementation patterns for GHR-GHR or PRLR-PRLR homomers, both GH and PRL caused decline in luciferase activity for GHR-PRLR heteromers. These and other data suggest that GHR and PRLR associate in complexes comprised of GHR-GHR/PRLR-PRLR heteromers consisting of GHR homodimers and PRLR homodimers, rather than GHR-PRLR heterodimers.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27003442      PMCID: PMC4853563          DOI: 10.1210/me.2015-1319

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  65 in total

1.  Intrinsically disordered cytoplasmic domains of two cytokine receptors mediate conserved interactions with membranes.

Authors:  Gitte W Haxholm; Louise F Nikolajsen; Johan G Olsen; Jacob Fredsted; Flemming H Larsen; Vincent Goffin; Stine F Pedersen; Andrew J Brooks; Michael J Waters; Birthe B Kragelund
Journal:  Biochem J       Date:  2015-04-07       Impact factor: 3.857

2.  A human prolactin antagonist, hPRL-G129R, inhibits breast cancer cell proliferation through induction of apoptosis.

Authors:  W Y Chen; P Ramamoorthy; N Chen; R Sticca; T E Wagner
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

Review 3.  The nature and regulation of the receptors for pituitary growth hormone.

Authors:  J P Hughes; H G Friesen
Journal:  Annu Rev Physiol       Date:  1985       Impact factor: 19.318

Review 4.  The role of prolactin in mammary carcinoma.

Authors:  Charles V Clevenger; Priscilla A Furth; Susan E Hankinson; Linda A Schuler
Journal:  Endocr Rev       Date:  2003-02       Impact factor: 19.871

5.  A JAK1/JAK2 chimera can sustain alpha and gamma interferon responses.

Authors:  F Kohlhuber; N C Rogers; D Watling; J Feng; D Guschin; J Briscoe; B A Witthuhn; S V Kotenko; S Pestka; G R Stark; J N Ihle; I M Kerr
Journal:  Mol Cell Biol       Date:  1997-02       Impact factor: 4.272

Review 6.  Prolactin involvement in breast cancer.

Authors:  B K Vonderhaar
Journal:  Endocr Relat Cancer       Date:  1999-09       Impact factor: 5.678

7.  Growth hormone-deficient dwarf animals are resistant to dimethylbenzanthracine (DMBA)-induced mammary carcinogenesis.

Authors:  Melinda M Ramsey; Rhonda L Ingram; Adrienne B Cashion; Amy H Ng; J Mark Cline; A F Parlow; William E Sonntag
Journal:  Endocrinology       Date:  2002-10       Impact factor: 4.736

8.  Multimeric growth hormone receptor complexes serve as signaling platforms.

Authors:  Magdalena Sedek; Lieke M van der Velden; Ger J Strous
Journal:  J Biol Chem       Date:  2013-11-26       Impact factor: 5.157

9.  Development of a novel ligand that activates JAK2/STAT5 signaling through a heterodimer of prolactin receptor and growth hormone receptor.

Authors:  John Fairbanks Langenheim; Wen Yuan Chen
Journal:  J Recept Signal Transduct Res       Date:  2009       Impact factor: 2.092

10.  Determinants of growth hormone receptor down-regulation.

Authors:  Luqin Deng; Kai He; Xiangdong Wang; Ning Yang; Chellappagounder Thangavel; Jing Jiang; Serge Y Fuchs; Stuart J Frank
Journal:  Mol Endocrinol       Date:  2007-05-08
View more
  4 in total

1.  Subdomain 2, Not the Transmembrane Domain, Determines the Dimerization Partner of Growth Hormone Receptor and Prolactin Receptor.

Authors:  Ying Liu; Jing Jiang; Bradford Lepik; Yue Zhang; Kurt R Zinn; Stuart J Frank
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

Review 2.  Targeting growth hormone function: strategies and therapeutic applications.

Authors:  Man Lu; Jack U Flanagan; Ries J Langley; Michael P Hay; Jo K Perry
Journal:  Signal Transduct Target Ther       Date:  2019-02-08

Review 3.  Growth Hormone Receptor Regulation in Cancer and Chronic Diseases.

Authors:  Ger J Strous; Ana Da Silva Almeida; Joyce Putters; Julia Schantl; Magdalena Sedek; Johan A Slotman; Tobias Nespital; Gerco C Hassink; Jan A Mol
Journal:  Front Endocrinol (Lausanne)       Date:  2020-11-18       Impact factor: 5.555

Review 4.  Classical and novel GH receptor signaling pathways.

Authors:  Stuart J Frank
Journal:  Mol Cell Endocrinol       Date:  2020-08-22       Impact factor: 4.102

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.